Ventus Therapeutics US Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic diseases, autoimmune diseases, and liver, renal, respiratory, ...

In a paper titled "Arachidonic acid inhibition of the NLRP3 inflammasome is a mechanism to explain the anti-inflammatory effects of fasting," published in Cell Reports, the team describes how fasting ...

NLRP3 is a member of a family of proteins known as inflammasome receptors and is a key component of the NLRP3 inflammasome, which is implicated in a host of diseases characterised by runaway ...

We are pleased to announce the progress that ZyVersa has made toward achieving our key near-term development milestones,” stated ...

Announcing a new publication for Acta Materia Medica journal. Herba Siegesbeckiae (HS) has been traditionally used for ...

highlights data from an article published in the peer-reviewed International Journal of Nanomedicine titled Small Intestinal Endocrine Cell Derived Exosomal ACE2 Protects Islet beta-Cell Function by ...

ZyVersa is a clinical-stage biopharmaceutical company with a laser focus on developing first-in-class drugs for diseases that currently have no effective treatments. Its portfolio includes two main ...